A next-generation plant
A « next-generation » facility under construction
In line with its international growth and development, LFB is developing its production capacity with a next-generation facility, currently under construction. This new facility should triple LFB’s overall capacity for producing plasma-derived medicinal products within ten years.
Manufacturing in France for the whole world
As from 2020 this plant, on a 40 acre site in Arras (Pas-de-Calais), will be producing liquid immunoglobulins, fibrinogen and albumin – all being medicinal products that are increasingly in demand in France and worldwide.
The new facility is designed principally to optimise production costs and respond to the highest global standards; it will therefore enable LFB to supply the whole world with products made in France.